Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Dearnaley

Showing results (61-70 of 148) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2019
Microbiota- and Radiotherapy-Induced Gastrointestinal Side-Effects (MARS) Study: A Large Pilot Study of the Microbiome in Acute and Late-Radiation EnteropathyMiguel Reis Ferreira, H Jervoise N Andreyev, Kabir Mohammed, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 23, 2016
Phase I/II trials of <sup>186</sup>Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survivalAna M Denis-Bacelar, Sarah J Chittenden, David P Dearnaley, et al.
BMC Medical Research Methodology|July 27, 2020
Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practiceAgnieszka Lemanska, Rachel C Byford, Clare Cruickshank, et al.
Physics in Medicine and Biology|March 15, 2017
A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastasesAna M Denis-Bacelar, Sarah J Chittenden, Iain Murray, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2012
Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignanciesLinda J Wedlake, Foteini Silia, Barbara Benton, et al.
European Urology|March 18, 2008
Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillanceNicholas J van As, Andrew R Norman, Karen Thomas, et al.
International Journal of Radiation Oncology, Biology, Physics|March 22, 2018
Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate CancerAnna C Wilkins, Barry Gusterson, Zsolt Szijgyarto, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 17, 2017
Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'Ana M Denis-Bacelar, Sarah J Chittenden, David P Dearnaley, et al.
The British Journal of Radiology|March 13, 2025
Radiation-induced lymphocyte apoptosis and chromosomic aberrations for prediction of toxicities in patients undergoing radical radiotherapy for breast or prostate cancersDavid Azria, Joanne S Haviland, Muriel Brengues, et al.
Cancer|September 22, 2007
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancerMichael A Carducci, Fred Saad, Per-Anders Abrahamsson, et al.
Pageof 15

Showing results (61-70 of 148) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2019
Microbiota- and Radiotherapy-Induced Gastrointestinal Side-Effects (MARS) Study: A Large Pilot Study of the Microbiome in Acute and Late-Radiation EnteropathyMiguel Reis Ferreira, H Jervoise N Andreyev, Kabir Mohammed, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 23, 2016
Phase I/II trials of <sup>186</sup>Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survivalAna M Denis-Bacelar, Sarah J Chittenden, David P Dearnaley, et al.
BMC Medical Research Methodology|July 27, 2020
Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practiceAgnieszka Lemanska, Rachel C Byford, Clare Cruickshank, et al.
Physics in Medicine and Biology|March 15, 2017
A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastasesAna M Denis-Bacelar, Sarah J Chittenden, Iain Murray, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2012
Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignanciesLinda J Wedlake, Foteini Silia, Barbara Benton, et al.
European Urology|March 18, 2008
Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillanceNicholas J van As, Andrew R Norman, Karen Thomas, et al.
International Journal of Radiation Oncology, Biology, Physics|March 22, 2018
Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate CancerAnna C Wilkins, Barry Gusterson, Zsolt Szijgyarto, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 17, 2017
Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'Ana M Denis-Bacelar, Sarah J Chittenden, David P Dearnaley, et al.
The British Journal of Radiology|March 13, 2025
Radiation-induced lymphocyte apoptosis and chromosomic aberrations for prediction of toxicities in patients undergoing radical radiotherapy for breast or prostate cancersDavid Azria, Joanne S Haviland, Muriel Brengues, et al.
Cancer|September 22, 2007
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancerMichael A Carducci, Fred Saad, Per-Anders Abrahamsson, et al.
Pageof 15